Brief: Poxel Announces Formation Of Scientific Advisory Board For Rare Metabolic Diseases

Poxel SA

06/12/2021 06:08

Dec 6 (Reuters) - POXEL SA  POXEL.PA :
    * POXEL ANNOUNCES FORMATION OF ITS SCIENTIFIC ADVISORY BOARD
FOR
RARE METABOLIC DISEASES
    * INITIATE PHASE 2A STUDIES FOR ALD IN EARLY 2022, WITH BOTH
PXL065, A NOVEL DEUTERIUM MODIFIED THIAZOLIDINEDIONE AND PXL770,
A FIRST-IN-CLASS DIRECT AMPK ACTIVATOR
    * NEW SAB WILL INITIALLY FOCUS ON SUPPORTING POXEL'S
X-LINKED
ADRENOLEUKODYSTROPHY (ALD) PROGRAM

Source text for Eikon:  ID:nBw5gFV6sa 
Further company coverage:  POXEL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))